Glufosfamide (Baxter Oncology).
Glufosfamide is a sugar phosphamide alkylating agent under development by Baxter Oncology (formerly ASTA Medica) as a potential treatment for cancer. By April 2000, glufosfamide had commenced phase II trials, one of which involved intrathecal administration to patients with carcinomatous meningioma.
Niculescu-Duvaz
Ion
I
CRC Centre for Cancer Therapeutics, Institute of Cancer Research, Sutton, Surrey, UK. ion@icr.ac.uk
D000818:Animals; D018906:Antineoplastic Agents, Alkylating / Q000494:pharmacology*; D002986:Clinical Trials as Topic; D005947:Glucose / Q000031:analogs & derivatives; D006801:Humans; D007069:Ifosfamide / Q000031:analogs & derivatives; D009369:Neoplasms / Q000188:drug therapy; D010752:Phosphoramide Mustards / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D013329:Structure-Activity Relationship
D018906:Antineoplastic Agents, Alkylating; D010752:Phosphoramide Mustards; C092028:beta-D-glucosylisophosphoramide mustard; D005947:Glucose; D007069:Ifosfamide